Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Related Articles
Savolitinib Combo Earns Priority Review in China for EGFR+ NSCLC
Findings from the phase 3 SACHI trial support the National Medical Products Administration’s priority review designation for savolitinib/osimertinib.
How family history knowledge can lead to cancer genetics intervention
Knowledge is power when it comes to family history and cancer risk.
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…
EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma
A marketing authorization application has been submitted to the EMA seeking the approval of eflornithine for patients with high-risk neuroblastoma.
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia
Amivantamab and Lazertinib Combo Extends Survival in EGFR+ NSCLC
The MARIPOSA study showed that the combination of amivantamab and lazertinib significantly improved overall survival over osimertinib in EGFR-mutated NSCLC.
What Seattle medical experts say about call to expand alcohol warning labels
The U.S. surgeon general on Friday called for updating alcohol warning labels to include cancer risk. Here’s how Seattle experts reacted to the announcement.
Study identifies genes linked to high prostate cancer mortality rates
Nature Africa – Researchers shed light on the genes that could be linked to the high mortality rates of prostate cancer among men of African…
Nivolumab/Ipilimumab Extends Survival in First-Line MSI-H/dMMR Metastatic Colorectal Cancer
Updated results from the phase 3 CheckMate-8HW trial continue to show fewer severe (grade 3/4) side effects with nivolumab/ipilimumab compared to chemotherapy.
